/images/ppid_59c68470-image-177001506912419086.webp)
In a regulatory filing, Lupin said it has entered a strategic collaboration with TB Alliance to advance the clinical development and commercialisation of Telacebec, an investigational drug for the treatment of tuberculosis (TB) and other mycobacterial diseases, including leprosy and Buruli ulcer.
Under the agreement, TB Alliance will continue to lead the clinical development of Telacebec, while Lupin will support the programme through its global manufacturing, regulatory and supply chain capabilities to enable wider patient access once approved.
Telacebec, formerly known as Q203, is being developed as a novel therapy for TB and related infections that continue to affect millions of people globally, particularly in low- and middle-income countries.
Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, said, “By leveraging our manufacturing scale and global
distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”
Mel Spigelman, President and CEO of TB Alliance, said Telacebec has the potential to transform treatment for long-neglected mycobacterial diseases. Partnering with Lupin, he noted, would help move the compound forward more efficiently while ensuring responsible development and access across geographies.
Separately, Lupin also announced the launch of Dasatinib Tablets in the United States after receiving approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA).
The product was developed in partnership with Pharmascience Inc. and is a generic version of Sprycel, an oncology drug used in the treatment of multiple forms of Philadelphia chromosome-positive chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) in both adult and paediatric patients.
According to the company, Dasatinib tablets had estimated annual sales of about $930 million in the US for the 12 months ended October 2025, highlighting the commercial significance of the launch in Lupin’s US generics portfolio.
In December, Swaminathan had unveiled the pharma major's plans to grow its specialty medicines business as part of its long-term strategy beyond generics. The shift he said is natural for Indian pharma and is “basically a question of evolution.”
Despite the two announcements, shares of Lupin were trading near the intraday lows. As of 11.20 am, the stock was trading 2.51% at ₹2,081.70. The stock has gained 10.60% in the past six months.
